Use of genetic and nongenetic factors in warfarin dosing algorithms

摘要: Despite the fact that warfarin has been used as an anticoagulant for many years, safety profile this drug poor. Inappropriate dosing continues to contribute significant morbidity and mortality due thrombotic disease bleeding. Therefore, there is a need development, characterization implementation of algorithms using patient's demographic information genotype. Recently, polymorphisms in two genes, cytochrome P450 2C9 vitamin K epoxide reductase complex 1, have shown affect warfarin's pharmacogenomics pharmacodynamics, respectively. Adding genotypes algorithm may enable better prediction initial than use data alone. An advisory committee US FDA voted on November 14, 2005, require manufacturers relabel their product, indicating genotyping recommended prior administration. The exact date when recommendation will be enacted remains determined. Successful into clinical practice requires results can translated directly decisions. development includes means achieve goal.